Clinical trial · Observational
Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer
Advancing Monitoring of NSCLC Treated With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) - Molecular Diagnosis on Circulating Tumor DNA
NCT02169349CI-TRIAL-00023837ANTiCIPecompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage IIIb and IV Non Small Cell Lung Cancer | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA Analysis | Genetic | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| Next Generation Sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Mutation profiling of circulating tumor DNA from plasma samples.
- timeFrame
- 1 year
- description
- To evaluate the sensitivity of NGS to detect the genetic alterations in plasma tumor DNA.
Secondary outcomes (1)
- measure
- Quantity of circulating tumor DNA in serially collected plasma specimens.
- timeFrame
- 1 year
- description
- To evaluate the change of quantity of circulating tumor DNA during treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed written informed consent * Male or female aged \>= 18 years * Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed Exclusion Criteria: * Tissue and plasma samples can not be provided for mutation analysis * Unwilling or unable to provide informed consent * Any serious medical condition that would interfere with the subject's safety
References
Publications (0)
Data not yet available
No reference posted for this study.